Het belang van astmamedicatie op maat bij kinderen: rationele en studiedesign van de PUFFIN-trial

E.M.A. Slob; S.J.H. Vijverberg; M.W. Pijnenburg; G.H. Koppelman; A.H. Maitland-van der Zee

Het belang van astmamedicatie op maat bij kinderen: rationele en studiedesign van de PUFFIN-trial

E.M.A. Slob
, S.J.H. Vijverberg
, M.W. Pijnenburg
, G.H. Koppelman
, A.H. Maitland-van der Zee^*

^*Corresponding author for this work

Pediatrics

Amsterdam UMC, Locatie UvA/AMC
Sophia Children's Hospital
Beatrix Kinderzieknhuis
University Medical Centre Groningen
Emma Children’s Hospital

Research output: Contribution to journal › Article › Professional

Abstract

Not every child responds equally well to asthma maintenance treatment. When a child does not respond well to a low dose of inhalation corticosteroids, the child will be treated with a higher dose of inhalation corticosteroids, or a long-acting beta-2-agonist (LABA) can be added to the existing therapy. However, some children benefit more from LABA treatment than others. This variation can be partially explained by a polymorphism in the gene that encodes the beta-2-receptor (the ADRB2 gene). The working mechanism of LABA depends on this receptor. It is possible to genotype this variant in the hospital. In June 2018, a Dutch, multicenter, randomised controlled trial (the PUFFIN trial) for children with asthma has started to investigate whether ADRB2 genotype guided treatment leads to better control of asthma and whether it is cost effective.

Original language	Dutch
Journal	Ned. Tijdschrift voor Allergie
Volume	19
Issue number	2
Publication status	Published - May 2019

Research programs

EMC OR-01-54-02

Access to Document

https://www.ntvaaki.nl/journal-article/het-belang-van-astmamedicatie-op-maat-bij-kinderen-rationale-en-studiedesign-van-de-puffin-trial/

Cite this

Slob, E. M. A., Vijverberg, S. J. H., Pijnenburg, M. W., Koppelman, G. H., & Maitland-van der Zee, A. H. (2019). Het belang van astmamedicatie op maat bij kinderen: rationele en studiedesign van de PUFFIN-trial. Ned. Tijdschrift voor Allergie, 19(2). https://www.ntvaaki.nl/journal-article/het-belang-van-astmamedicatie-op-maat-bij-kinderen-rationale-en-studiedesign-van-de-puffin-trial/

@article{475829b667454c34a03eb41fed021e4b,

title = "Het belang van astmamedicatie op maat bij kinderen: rationele en studiedesign van de PUFFIN-trial",

abstract = "Not every child responds equally well to asthma maintenance treatment. When a child does not respond well to a low dose of inhalation corticosteroids, the child will be treated with a higher dose of inhalation corticosteroids, or a long-acting beta-2-agonist (LABA) can be added to the existing therapy. However, some children benefit more from LABA treatment than others. This variation can be partially explained by a polymorphism in the gene that encodes the beta-2-receptor (the ADRB2 gene). The working mechanism of LABA depends on this receptor. It is possible to genotype this variant in the hospital. In June 2018, a Dutch, multicenter, randomised controlled trial (the PUFFIN trial) for children with asthma has started to investigate whether ADRB2 genotype guided treatment leads to better control of asthma and whether it is cost effective.",

author = "E.M.A. Slob and S.J.H. Vijverberg and M.W. Pijnenburg and G.H. Koppelman and \{Maitland-van der Zee\}, A.H.",

year = "2019",

month = may,

language = "Dutch",

volume = "19",

number = "2",

}

Slob, EMA, Vijverberg, SJH, Pijnenburg, MW, Koppelman, GH & Maitland-van der Zee, AH 2019, 'Het belang van astmamedicatie op maat bij kinderen: rationele en studiedesign van de PUFFIN-trial', Ned. Tijdschrift voor Allergie, vol. 19, no. 2. <https://www.ntvaaki.nl/journal-article/het-belang-van-astmamedicatie-op-maat-bij-kinderen-rationale-en-studiedesign-van-de-puffin-trial/>

TY - JOUR

T1 - Het belang van astmamedicatie op maat bij kinderen

T2 - rationele en studiedesign van de PUFFIN-trial

AU - Slob, E.M.A.

AU - Vijverberg, S.J.H.

AU - Pijnenburg, M.W.

AU - Koppelman, G.H.

AU - Maitland-van der Zee, A.H.

PY - 2019/5

Y1 - 2019/5

N2 - Not every child responds equally well to asthma maintenance treatment. When a child does not respond well to a low dose of inhalation corticosteroids, the child will be treated with a higher dose of inhalation corticosteroids, or a long-acting beta-2-agonist (LABA) can be added to the existing therapy. However, some children benefit more from LABA treatment than others. This variation can be partially explained by a polymorphism in the gene that encodes the beta-2-receptor (the ADRB2 gene). The working mechanism of LABA depends on this receptor. It is possible to genotype this variant in the hospital. In June 2018, a Dutch, multicenter, randomised controlled trial (the PUFFIN trial) for children with asthma has started to investigate whether ADRB2 genotype guided treatment leads to better control of asthma and whether it is cost effective.

AB - Not every child responds equally well to asthma maintenance treatment. When a child does not respond well to a low dose of inhalation corticosteroids, the child will be treated with a higher dose of inhalation corticosteroids, or a long-acting beta-2-agonist (LABA) can be added to the existing therapy. However, some children benefit more from LABA treatment than others. This variation can be partially explained by a polymorphism in the gene that encodes the beta-2-receptor (the ADRB2 gene). The working mechanism of LABA depends on this receptor. It is possible to genotype this variant in the hospital. In June 2018, a Dutch, multicenter, randomised controlled trial (the PUFFIN trial) for children with asthma has started to investigate whether ADRB2 genotype guided treatment leads to better control of asthma and whether it is cost effective.

M3 - Article

SN - 1568-2498

VL - 19

JO - Ned. Tijdschrift voor Allergie

JF - Ned. Tijdschrift voor Allergie

IS - 2

ER -